RAD001 Plus Carboplatin in Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: RAD001|DRUG: Carboplatin
Sponsor: NYU Langone Health
Collaborators: Novartis Pharmaceuticals